Menu Search
Equities

Caribou Biosciences Inc

CRBU:NSQ

Caribou Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.35
  • Today's Change-0.445 / -15.95%
  • Shares traded1.94m
  • 1 Year change-39.09%
  • Beta2.4162
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Caribou Biosciences Inc grew revenues 148.91% from 13.85m to 34.48m while net income improved from a loss of 99.42m to a smaller loss of 102.07m.
Gross margin--
Net profit margin-1,290.81%
Operating margin-1,439.50%
Return on assets-36.94%
Return on equity-43.60%
Return on investment-39.76%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Caribou Biosciences Inc fell by 7.18m. Cash Flow from Financing totalled 154.30m or 447.54% of revenues. In addition the company used 93.29m for operations while cash used for investing totalled 68.18m.
Cash flow per share-1.61
Price/Cash flow per share--
Book value per share3.11
Tangible book value per share3.11
More ▼

Balance sheet in USDView more

Caribou Biosciences Inc uses little or no debt in its capital structure.
Current ratio7.38
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.